Immunogenicity and Safety of Two Formulations of GSK Biologicals' Pneumococcal Vaccine (2830929A and 2830930A) When Administered in Healthy Infants

GSK Investigational Site, Prague

GSK Investigational Site, Berlin

GSK Investigational Site, Berlin

GSK Investigational Site, Flensburg

GSK Investigational Site, Antequera/Málaga

GSK Investigational Site, Löhne

GSK Investigational Site, Detmold

GSK Investigational Site, Domažlice

GSK Investigational Site, Jindřichův Hradec

GSK Investigational Site, Wanzleben

GSK Investigational Site, Seville

GSK Investigational Site, Liberec

GSK Investigational Site, Valencia

GSK Investigational Site, Valladolid

GSK Investigational Site, Kleve-Materborn

GSK Investigational Site, Wroclaw

GSK Investigational Site, Trier

GSK Investigational Site, Frankenthal

GSK Investigational Site, Stuttgart

GSK Investigational Site, Ostrava - Poruba

GSK Investigational Site, Schwäbisch Hall

GSK Investigational Site, Lipník nad Bečvou

GSK Investigational Site, Kehl

GSK Investigational Site, Munich

GSK Investigational Site, Olching

GSK Investigational Site, Berchtesgaden

GSK Investigational Site, Kirchheim

GSK Investigational Site, Benešov

GSK Investigational Site, Děčín

GSK Investigational Site, Kladno

GSK Investigational Site, Náchod

GSK Investigational Site, Ostrov

GSK Investigational Site, Pardubice

GSK Investigational Site, Pilsen

GSK Investigational Site, Dębica

GSK Investigational Site, Oleśnica

GSK Investigational Site, Siemianowice Śląskie

GSK Investigational Site, Torun

GSK Investigational Site, Trzebnica

GSK Investigational Site, Warsaw

GSK Investigational Site, Almería

GSK Investigational Site, Burgos